Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development.

The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in ...

Akceso Advisors AG Akceso is a specialist pricing, reimbursement & market access consultancy providing innovative tools to optimise opportunities. Headquartered in Basel, Switzerland, Akceso is ...

Briggids is a dynamic, global organisation with extensive experience in systematic reviews, health technology assessments, therapeutic value propositions/market access, landscape mapping and medical ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...

Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...

Hospitals engaging in industry partnerships were found to be up to 2.5 times more likely to follow NICE guidelines Research commissioned by the Association of the British Pharmaceutical Industry (ABPI ...